Osteomalacia occurs in patients with a variety of disorders affecting the stomach and small bowel, especially when associated with steatorrhoea. The pathogenesis of this osteomalacia has in part been explained by malabsorption of vitamin D,1 but other factors, including diminished intake of foods containing vitamin D, too little sunlight, and interruption of the enterohepatic circulation of 25-hydroxyvitamin D3(25-OH-D3) have been suggested.2
Because it is widely assumed that vitamin D is poorly absorbed in malabsorptive states, parenteral therapy is often given to patients both for treatment and prophylaxis of vitamin D deficiency and it has recently been suggested that the use of vitamin D metabolites and their analogues may offer certain advantages over the parent vitamin.3 The present investigation was undertaken to study the simultaneous absorption of orally administered 3H 25-OH-D3 and 14C vitamin D3 in control subjects and patients with various disorders of the upper gastrointestinal tract. 25 , ug (2 uCi) [4-14C] vitamin D3 and 26 , ug (8 uCi) 25-[26,27-3H] 25-OH-D3 dissolved in 1-0 ml ethanol and mixed with 200 ml of milk after a light breakfast. Blood samples were drawn two hourly for eight hours and then at regular intervals for 13 days after the administration of the tracers. Faeces were collected for the four days and urine for the three days after the ingestion of the vitamin preparations. All patients received a standard 90 g fat diet with the 287 (Table 2 ).
The maximum concentration of 3H 25-OH-D3 was always higher than that of 14C vitamin D3 and was reached significantly earlier (P<0.01).
FAECAL RADIOACTIVITY
The net intestinal absorption of 14C vitamin D3 and 3H 25-OH-D3 is shown in Table 2 ; it can be seen that only the short bowel group of patients differed from the controls. The relationship between absorption of vitamin D3 and 3H 25-OH-D3 and faecal fat excretion in the individual patients was examined. A strong and significant negative relationship exists in those patients with steatorrhoea, faecal fat excretion >20 mmol/day (Fig. 3) but not in patients with normal faecal fat excretion.
In individual patients with malabsorption the net intestinal absorption of 3H 25-OH-D3 was significantly greater than that of 14C vitamin D3 (P<0.01). Although there was a tendency for 3H 25-OH-D3 absorption to be greater than 14C vitamin D3 where the faecal fat excretion was normal, the differences were insignificant (P>01).
In three patients (7, 8, 13) Even in the presence of the gross steatorrhoea found in the short bowel group of patients, at least 40% of the 14C vitamin D3 and 60% of 3H 25-OH-D3 was absorbed and, while in this situation malabsorption of vitamin D may contribute to the development of vitamin D deficiency and osteomalacia, the provision of vitamin D in slightly larger doses than are used in simple vitamin D deficiency should suffice in the management of these patients. Since 450 units of vitamin D2 are more than enough to correct simple vitamin D deficiency, 900 units/day were considered sufficient for patients with malabsorption.
An excellent clinical and biochemical response followed treatment with 900 units of vitamin D2 in patient 15, achieving serum 25-OH-D concentrations of 20-30 ng/ml and, although patient 14 initially received 50 000 units daily of vitamin D2, the serum 25-OH-D concentration remains above 20 ng/ml on prolonged treatment with 900 units of vitamin D2 daily.
The present data show that malabsorption of vitamin D is not a universal problem in patients with intestinal disease, and that vitamin D deficiency can be cured or prevented by relatively small oral doses of vitamin D2. Such treatment avoids the necessity of regular injections and the hazards of hypercalcaemia from large oral doses of vitamin D or the newer more potent vitamin D metabolites. 
